BioArctic AB (publ) är ett
History – BioArctic Ground-breaking discoveries originating from Swedish research BioArctic was founded in by Professor Lars Lannfelt and Dr. Pär Gellerfors to develop important breakthrough discoveries made by Professor Lannfelt regarding Alzheimer’s disease.
Bioarctics grundare och storägare Pär
Pär Gellerfors is together with Lars Lannfelt the founder of BioArctic. Pär Gellerfors is Associate Professor of Biochemistry at Stockholm University. He is also co-founder of HemeBiotech/Zymenex A/S and has held several board memberships. Born: Eugen Steiner · Cecilia Edström ·
Stockholm, October 25, – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has been made aware that the company’s two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, intend to divest a minor part of their respective shareholding. —. BioArctic's co-founder, Pär Gellerfors, unfortunately
Founder of BioArctic AB and Zymenex A, Pär Lars Gellerfors is a businessperson who has been at the head of 5 different companies and currently occupies the position of Director & Senior Vice President-Business Strategy at BioArctic AB. He is also Associate Professor at the University of Stockholm and on the board of 6 other companies. Företaget BioArctic grundades när
BioArctic, the company he co-founded in with Pär Gellerfors, struck a licensing deal on the monoclonal antibody therapy with Eisai in , entitling it to hundreds of millions of dollars in. Gellerfors kommer att lämna sin
Pär Gellerfors Board member More Lars Lannfelt Board member More Lotta Ljungqvist Board member More Mikael Smedeby Board member More Ivar Verner Vice Chairman and Board member *Includes holdings by self, closely associated persons, controlled companies or in capital insurance accounts. Quick links 9/15/, AM SEK BIOA B (Stockholm). Pär Lars Gellerfors. Man, född
Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association; Alzheimer’s & Dementia: Translational Research & Clinical Interventions. STOCKHOLM (Nyhetsbyrån Direkt) Bioarctics två
The symptomatic drugs currently on the market for Alzheimer’s disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly in the last decade is immunotherapy: vaccines and, especially, passive vaccination with monoclonal antibodies. Antibodies are attractive drugs as they can be made highly specific for.